Shares of Aeterna Zentaris Inc. (NASDAQ:AEZS) were down 4.4% on Wednesday . The company traded as low as $3.40 and last traded at $3.45, with a volume of 167,498 shares changing hands. The stock had previously closed at $3.61.

A number of analysts have recently weighed in on AEZS shares. Maxim Group reiterated a “buy” rating and set a $11.00 target price on shares of Aeterna Zentaris in a research report on Monday, May 2nd. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Aeterna Zentaris in a research report on Sunday, July 10th.

The firm has a 50 day moving average of $3.41 and a 200 day moving average of $3.47. The firm’s market capitalization is $34.29 million.

Aeterna Zentaris (NASDAQ:AEZS) last issued its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.82) by $0.11. Analysts predict that Aeterna Zentaris Inc. will post ($2.84) earnings per share for the current year.

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.